Effect of high dose progestin on serum lipids

      This paper is only available as a PDF. To read, Please Download here.


      The effect of high dose medroxyprogesterone (MPA) on serum lipids was studied in 31 postmenopausal patients with endometrial cancer. After 3 months of MPA treatment, total cholesterol decreased by 18% (P < 0.001), LDL cholesterol by 16% (P < 0.01) and HDL cholesterol by 38% (P < 0.001) from the respective pretreatment values; correspondingly, the ratio of HDL to total cholesterol decreased (P < 0.001). Similar changes were found as early as 2 weeks after start of treatment. In the 15 controls receiving no progestin treatment, full dose intracavitary ratiotherapy and gynecological surgery had no effect on these serum lipids.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Bradley D.D.
        • Wingerd J.
        • Petitti D.B.
        • Krauss R.M.
        • Ramcharan S.
        Serum high-density-lipoprotein cholesterol in women using oral contraceptives, estrogens and progestins.
        N. Engl. J. Med. 1978; 299: 17
        • Olsson A.
        • Orö L.
        • Rössner S.
        Effects of oxandrolone on plasma lipoproteins and the intravenous fat tolerance in man.
        Atherosclerosis. 1974; 19: 337
        • Tamai T.
        • Nakai T.
        • Yamada S.
        • Kobayashi T.
        • Hayashi T.
        • Kutsumi Y.
        • Takeda R.
        Effects of oxandrolone on plasma lipoproteins in patients with type IIa, IIb and IV hyperlipoproteinemia — Occurrence of hypo-high density lipoproteinemia.
        Artery. 1979; 5: 125
        • Tikkanen M.
        • Nikkilä E.A.
        • Kuusi T.
        • Sipinen S.
        Different effects of two progestins on plasma high density lipoprotein (HDL2) and postheparin plasma hepatic lipase activity.
        Atherosclerosis. 1981; 40: 365
        • Hirvonen E.
        • Mälkönen M.
        • Manninen V.
        Effects of different progestagens on lipoproteins during postmenopausal replacement therapy.
        N. Engl. J. Med. 1981; 304: 560
        • Badzio T.
        • Boscon H.
        The determination of free and esterified cholesterol in blood after separation by thinlayer chromatography.
        Clin. Chim. Acta. 1966; 13: 794
        • Carlson L.A.
        Determination of serum triglycerides.
        J. Atheroscler. Res. 1963; 3: 334
        • Viikari J.
        Precipitation of plasma lipoproteins by PEG-6000 and its evaluation with electrophoresis and ultracentrifugation.
        Scand. J. Clin. Lab. Invest. 1976; 36: 265
        • Beaumont J.L.
        • Carlson L.A.
        • Cooper G.R.
        • Fejfar Z.
        • Fredrickson D.S.
        • Strasser T.
        Classification of hyperlipidaemias and hyperlipoproteinaemias.
        Bull. WHO. 1970; 43: 891
      1. Lancet. 1977; ii: 727
        • Stadel B.V.
        Oral contraceptives and cardiovascular disease.
        N. Engl. J. Med. 1981; 305: 672
        • Gustafson A.
        • Svanberg A.
        Gonadal steroid effects on plasma lipoproteins and individual phospholipids.
        J. Clin. Endocrinol. 1972; 35: 203
        • Feinleib M.
        On a possible inverse relationship between serum cholesterol and cancer mortality.
        Amer. J. Epidemiol. 1981; 114: 5